IL6 and congenital rubella syndrome: Siltuximab, on the other hand, is a small molecule capable of directly binding circulating IL-6 rather than the IL-6 receptor and therefore it is believed to be the agent of choice to control CRS and ICANS, preserving brain tissue from damages resulting from high levels of inflammation (41).